(P103) Socioeconomic Status and Overall Survival Following Hepatocellular Carcinoma Diagnosis in an Urban Academic Cancer Center

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, the incidence of which is increasing in the United States. In this report, we analyze predictors of overall survival (OS) for a large cohort of patients diagnosed with HCC at an urban academic cancer center.

Nitin Ohri, MD, Chandan Guha, MD, PhD, Andreas Kaubisch, MD, Santiago Aparo, MD, Jonathan M. Schwartz, MD, Madhur K. Garg, MD; Montefiore Medical Center, Albert Einstein College of Medicine

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, the incidence of which is increasing in the United States. In this report, we analyze predictors of overall survival (OS) for a large cohort of patients diagnosed with HCC at an urban academic cancer center.

Methods: We queried our institution’s tumor registry to identify all patients diagnosed with HCC in the years 2000–2011. Patients for whom adequate demographic, clinical, and treatment data were available were included in this analysis. An institutional database was referenced to obtain a quantitative estimate of each patient’s socioeconomic status (SES) using “neighborhood” information, such as median household income, housing unit values, education level, and occupation statistics. SES was reported as a z-score compared with the national average and dichotomized at the median value for statistical analyses. Bivariate and multivariate Cox proportional hazards modeling was used to identify predictors of OS.

Results: A total of 683 patients met the eligibility criteria for this analysis. Median SES for the cohort was –3.39, with an interquartile range of –6.35 to –1.18. Median follow-up for living patients was 16.0 months. Median survival for all patients was 11.4 months, with 1-, 2-, and 3-year actuarial survival rates of 49%, 34%, and 28%, respectively. On bivariate analyses, advanced age, advanced American Joint Committee on Cancer (AJCC) stage, high Model for End-Stage Liver Disease (MELD) score, decreased serum albumin, decreased serum sodium, and lack of local/locoregional therapy were all associated with decreased OS. In the final multivariate model, statistically significant independent predictors of OS were age (hazard ratio [HR] = 1.17 per decade; 95% confidence interval [CI], 1.08–1.27; P < .001), male gender (HR = 1.34; 95% CI, 1.07–1.67; P = .010), stage (HR = 1.45 for stage 3–4 vs stage 1–2; 95% CI, 1.18–1.77; P < .001), MELD score (HR = 1.04 per unit increase; 95% CI, 1.02–1.05; P < .001), albumin (HR = 0.73 per g/dL; 95% CI, 0.63–0.84; P < .001), use of local/locoregional therapy (HR = 0.48; 95% CI, 0.38–0.60; P < .001), and SES (HR = 1.24 for patients below median value; 95% CI, 1.03–1.51; P = .027).

Conclusion: In addition to established prognostic factors, we have identified SES as an independent predictor of survival following HCC diagnosis. Additional study to understand this phenomenon is warranted.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content